Advertisement

A rational approach to identifying a fundamentally new drug for the treatment of migraine

  • P. P. A. Humphrey
  • E. Apperley
  • W. Feniuk
  • M. J. Perren
Chapter
Part of the Developments in CardioCardiovascular Pharmacology of 5-Hydroxytryptamine book series (DICM, volume 106)

Abstract

As early as about AD 50, Aretaeus of Cappadocia is said to have recognised the symptoms of what is now known as migraine, describing the characteristic unilateral headache associated with nausea and symptom-free periods between attacks. More than two thousand years on we still do not understand the aetiology of this often debilitating disease which afflicts up to 10% of the western world. There is however a lot of circumstantial evidence that somehow the ubiquitous, yet until recently almost enigmatic, biogenic amine, 5-hydroxytryptamine (5-HT), is involved.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Sicuteri F, Testi A, Anselmi B (1961): Biochemical investigations in headache: Increase in the hydroxyindoleacetic acid excretion during migraine attacks. Int Arch Allergy 19: 55–58.CrossRefGoogle Scholar
  2. 2.
    Anthony M, Hinterberger H, Lance JW (1967): Plasma serotonin in migraine and stress. Arch Neurol 16: 544–552.PubMedCrossRefGoogle Scholar
  3. 3.
    Carroll JD, Hilton BP (1974): The effects of reserpine injection on methysergide treated control and migrainous subjects. Headache 14: 149–156.PubMedCrossRefGoogle Scholar
  4. 4.
    Fozard JR (1982): Mechanism of the hypotensive effect of ketanserin. J Cardiovasc Pharmacol 4: 829–838.PubMedCrossRefGoogle Scholar
  5. 5.
    Graham JR, Wolff HG (1938): Mechanism of migraine headache and action of ergotamine tartrate. Archs Neurol Psychiat, Chicago 39: 737.CrossRefGoogle Scholar
  6. 6.
    Wolff HG (1963): Headache and other head pain . London: Oxford University Press.Google Scholar
  7. 7.
    Kimball RW, Friedman AP, Vallejo E (1960): Effect of serotonin in migraine patients. Neurology 10: 107–111.PubMedCrossRefGoogle Scholar
  8. 8.
    Lance JW (1973): The mechanism and management of headache . Second Edition, London: Butterworth Publishers.Google Scholar
  9. 9.
    Lance JW, Anthony M, Somerville B (1970): Comparative trial of serotonin antagonists in the management of migraine. Br Med J 2: 327–330.PubMedCentralPubMedCrossRefGoogle Scholar
  10. 10.
    Humphrey PPA, Feniuk W, Watts AD (1982): Ketanserin — a novel hypertensive drug? J Pharm Pharmacol 34: 541.PubMedCrossRefGoogle Scholar
  11. 11.
    Saxena PR (1974): Selective vasoconstriction in carotid vascular bed by methysergide: Possible relevance to its antimigraine effect. Eur J Pharmacol 27: 99–105.PubMedCrossRefGoogle Scholar
  12. 12.
    Saxena PR (1972): The effects of antimigraine drugs on the vascular responses by 5-hydroxytryptamine and related biogenic substances on the external carotid bed of dogs: possible pharmacological implications to their antimigraine action. Headache 12: 44–54.PubMedCrossRefGoogle Scholar
  13. 13.
    Apperley E, Humphrey PPA, Levy GP (1976): Receptors for 5-hydroxytryptamine and noradrenaline in rabbit isolated ear artery and aorta. Br J Pharmacol 58: 211–221.PubMedCrossRefGoogle Scholar
  14. 14.
    Apperley E, Humphrey PPA, Levy GP (1977): Two types of excitatory receptor for 5-hydroxytryptamine in dog vasculature? Br J Pharmacol 61: 46 50 P.Google Scholar
  15. 15.
    Apperley E, Feniuk W, Humphrey PPA, Levy GP (1980): Evidence for two types of excitatory receptor for 5-hydroxytryptamine in dog isolated vasculature. Br J Pharmacol 68: 215–224.PubMedCrossRefGoogle Scholar
  16. 16.
    Feniuk W, Humphrey PPA, Perren MJ, Watts AD (1985): A comparison of 5-hydroxy- tryptamine receptors mediating contraction in rabbit aorta and dog saphenous vein. Evidence for different receptor types obtained by use of selective agonists and antagonists. Br J Pharmacol 86: 697–704.PubMedCrossRefGoogle Scholar
  17. 17.
    Apperley E, Humphrey PPA (1986): The interaction of 5-hydroxytryptamine and methysergide with methiothepin at “5-HT,-like” receptors in dog saphenous vein. Br J Pharmacol 87:13IP.Google Scholar
  18. 18.
    Gunning SJ, Bunce KT, Humphrey PPA (1988): Methysergide contracts guinea-pig ileum via histamine H1 receptors. Br J Pharmacol 93: 238 P.Google Scholar
  19. 19.
    Berde B, Schild HO (Eds) (1978): Ergot alkaloids and related compounds . Berlin: Springer-Verlag.Google Scholar
  20. 20.
    Dalton DW, Feniuk W, Humphrey PPA (1986): An investigation into the mechanisms of the cardiovascular effects of 5-hydroxytryptamine in conscious normotensive and doca- salt hypertensive rats. J Auton Pharmacol 6: 219–228.PubMedCrossRefGoogle Scholar
  21. 21.
    Connor HE, Feniuk W, Humphrey PPA, Perren MJ (1986): 5-Carboxamidotryptamine is a selective agonist at 5-hydroxytryptamine receptors mediating vasodilatation and tachycardia in anaesthetized cats. Br J Pharmacol 87:417–426.PubMedCrossRefGoogle Scholar
  22. 22.
    Feniuk W, Humphrey PPA, Hunt AAE (1985): The haemodynamic profile and mechanism of the hypotensive action of 5-carboxamidotryptamine in conscious dogs. Br J Pharmacol 85: 31 OP.Google Scholar
  23. 23.
    Eyre P (1975): Atypical tryptamine receptors in sheep pulmonary vein. Br J Pharmacol 55: 329–333.PubMedCrossRefGoogle Scholar
  24. 24.
    Feniuk W, Humphrey PPA, Watts AD (1983): 5-Hydroxytryptamine-induced relaxation of isolated mammalian smooth muscle. Eur J Pharmacol 96:71–78.PubMedCrossRefGoogle Scholar
  25. 25.
    Feniuk W, Humphrey PPA, Watts AD (1984): 5-Carboxamido-tryptamine – a potent agonist at 5-hydroxytryptamine receptors mediating relaxation. Br J Pharmacol 82:209P.Google Scholar
  26. 26.
    Trevethick MA, Feniuk W, Humphrey PPA (1984): 5-Hydroxytryptamine-induced relaxation of neonatal porcine vena cavain vitro. Life Sci 35:477–486.PubMedCrossRefGoogle Scholar
  27. 27.
    Trevethick MA, Feniuk W, Humphrey PPA (1986): 5-Carboxamidotryptamine: a potent agonist mediating relaxation and elevation of cyclic AMP in the isolated neonatal porcine vena cava. Life Sci 38:1521–1528.PubMedCrossRefGoogle Scholar
  28. 28.
    Sumner MJ, Humphrey PPA, Feniuk W (1987): Characterisation of the 5-HT1-like receptor mediating relaxation of porcine vena cava. Br J Pharmacol 92: 574 P.Google Scholar
  29. 29.
    Sumner MJ, Feniuk W, Humphrey PPA (1989): Further characterisation of the 5-HT receptor mediating vascular relaxation and elevation of cyclic AMP in isolated porcine vena cava. Br J Pharmacol 97: 292–300.PubMedCrossRefGoogle Scholar
  30. 30.
    Bradley PB, Engel G, Feniuk W, Fozard JR, Humphrey PPA, Middlemiss DN, Mylecharane EJ, Richardson BP, Saxena PR (1986): Proposals for the classification and nomenclature of functional receptors for 5-hydroxytryptamine. Neuropharmacology 25: 563–576.PubMedCrossRefGoogle Scholar
  31. 31.
    Humphrey PPA (1984): Peripheral 5-hydroxytryptamine receptors and their classification. Neuropharmacology 23: 1503–1510.PubMedCrossRefGoogle Scholar
  32. 32.
    Humphrey PPA, Feniuk W (1987): Classification of functional 5-hydroxytryptamine receptors, pp. 277–280 in: Rand MJ, Raper (eds), Pharmacology, International Congress Series 750 (Proceedings of Xth International Congress of Pharmacology – I.U.P.H.A.R.) . Netherlands: Elsevier Science Publishers.Google Scholar
  33. 33.
    Feniuk W, Humphrey PPA (1989): Mechanisms of 5-hydroxytryptamine-induced vasoconstriction, pp. 100–122, in Fozard JR (ed), The Peripheral Actions of 5-Hydroxy- tryptamine . London: Oxford University Press.Google Scholar
  34. 34.
    Feniuk W, Humphrey PPA (1989): Mechanisms of 5-hydroxytryptamine-induced vasoconstriction, pp. 100–122, in Fozard JR (ed), The Peripheral Actions of 5-Hydroxy- tryptamine . London: Oxford University Press.Google Scholar
  35. 35.
    Feniuk W, Humphrey PPA (1989): Mechanisms of 5-hydroxytryptamine-induced vasoconstriction, pp. 100–122, in Fozard JR (ed), The Peripheral Actions of 5-Hydroxy- tryptamine . London: Oxford University Press.Google Scholar
  36. 36.
    Watts AD, Feniuk W, Humphrey PPA (1981): A pre-junctional action of 5-hydroxytryptamine and methysergide on noradrenergic nerves in dog isolated saphenous vein. J Pharm Pharmacol 33: 515–520.PubMedCrossRefGoogle Scholar
  37. 37.
    Feniuk W, Humphrey PPA, Watts AD (1981): Further characterisation of pre- and postjunctional receptors for 5-hydroxytryptamine in isolated vasculature. Br J Pharmacol 73: 191P–192P.Google Scholar
  38. 38.
    Feniuk W, Humphrey PPA, Watts AD (1981): Modification of the vasomotor actions of methysergide in the femoral arterial bed of the anaesthetised dog by changes in sympathetic nerve activity. J Auton Pharmacol 1: 127–132.PubMedCrossRefGoogle Scholar
  39. 39.
    Doenicke A, Siegel E, Hadoke M, Perrin VL (1987): Initial clinical study of AH25086B (5-HT1-like agonist) in the acute treatment of migraine. Cephalalgia 7 (6): 438–439.Google Scholar
  40. 40.
    Brand J, Hadoke M, Perrin VL (1987): Placebo controlled study of a selective 5-HT1-like agonist, AH25086B, in relief of acute migraine. Cephalalgia 7(6): 402–403.Google Scholar
  41. 41.
    Humphrey PPA, Feniuk W, Perren MJ, Connor HE, Oxford AW, Coates IH, Butina D (1988): GR43175, a selective agonist for the 5-HT1-like receptor in dog isolated saphenous vein. Br J Pharmacol 94: 1123–1132.PubMedCrossRefGoogle Scholar
  42. 42.
    Feniuk W, Humphrey PPA, Perren MJ (1989): The selective carotid arterial vasoconstrictor action of GR43175 in anaesthetised dogs. Br J Pharmacol 96: 83–90.PubMedCrossRefGoogle Scholar
  43. 43.
    Perren MJ, Feniuk W, Humphrey PPA (1989): The selective closure of feline carotid arteriovenous anastomoses by GR43175. Cephalalgia 9 (Suppl. 9): 41–46.PubMedGoogle Scholar
  44. 44.
    Humphrey PPA, Perren MJ, Feniuk W, Oxford AW (1989): The pharmacology of the novel 5-HT1-like receptor agonist GR43175. Cephalalgia 9 (Suppl. 9): 23–33.PubMedGoogle Scholar
  45. 45.
    Johnston BM, Saxena PR (1978): The effect of ergotamine on tissue blood flow and the arteriovenous shunting of radioactive microspheres in the head. Br J Pharmacol 63: 541–549.PubMedCrossRefGoogle Scholar
  46. 46.
    Neilsen TH, Tfelt-Hansen P (1989): Lack of effect of GR43175 on peripheral arteries in man. Cephalalgia 9 (Suppl. 9): 93–95.Google Scholar
  47. 47.
    Feniuk W, Humphrey PPA, Perren MJ (1989): GR43175 does not share the complex pharmacology of the ergots. Cephalalgia 9 (Suppl. 9): 35–39.PubMedGoogle Scholar
  48. 48.
    Saxena PR, Bom AH, Verdouw PD (1989): Characterization of 5-hydroxytryptamine receptors in the cranial vasculature. Cephalalgia 9 (Suppl. 9): 15–22.PubMedGoogle Scholar
  49. 49.
    Fozard JR (1987): 5-HT: The enigma variations. Trends Pharmacol Sci 501–506.Google Scholar
  50. 50.
    Doenicke A, Brand J, Perrin VL (1988): Possible benefit of GR43175, a novel 5-HT1- like receptor agonist, for the acute treatment of severe migraine. Lancet 1: 1309–1311.PubMedCrossRefGoogle Scholar
  51. 51.
    Perrin VL, F0ärkkilä M, Goasguen J, Doenicke A, Brand J, Tfelt-Hansen P (1989): Overview of initial clinical studies with intravenous and oral GR43175 in acute migraine. Cephalalgia 9 (Suppl. 9): 63–72.PubMedGoogle Scholar
  52. 52.
    Humphrey PPA, Feniuk W, Perren MJ, Oxford AW, Brittain RT (1989): Sumatriptan Succinate. Drugs of the Future 14 (1): 35–39.Google Scholar
  53. 53.
    Dallas FAA, Dixon CM, McCulloch RJ, Saynor DA (1989): The kinetics of 14C- GR43175 in rat and dog. Cephalalgia 9 (Suppl. 9): 53–56.PubMedGoogle Scholar
  54. 54.
    Fowler PA, Thomas M, Lacey LF, Andrew P, Dallas FAA (1989): Early studies with the novel 5-HT1-like agonist GR43175 in healthy volunteers. Cephalalgia 9 (Suppl. 9): 57–62.PubMedGoogle Scholar
  55. 55.
    Doenicke A, Melchart D, Bayliss EM (1989): Effective improvement of symptoms in patients with acute migraine with GR43175 dispersible tablets. Cephalalgia 9 (Suppl. 9): 89–92.PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media Dordrecht 1990

Authors and Affiliations

  • P. P. A. Humphrey
  • E. Apperley
  • W. Feniuk
  • M. J. Perren

There are no affiliations available

Personalised recommendations